• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Relief Therapeutics Hldg Ag (OP:RLFTF)

    1.420 +0.010 (+0.71%)
    Streaming Delayed Price Updated: 2:17 PM EST, Feb 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Relief Therapeutics Hldg Ag

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Shareholders Approve Business Combination with NeuroX
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Publishes 2025 Half-Year Report
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Advances Publication of 2025 Half-Year Report
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Announces Results of Annual General Meeting
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Secures up to $11 Million from Royalty Sales
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
    Via ACCESS Newswire
    News headline image
    Relief Therapeutics Provides Update on Potential Transaction with Renexxion
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024
    Via ACCESSWIRE
    News headline image
    Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
    Via ACCESSWIRE
    News headline image
    RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.